Limerston-backed Prism acquires Repose
Limerston Capital has supported its portfolio company Prism Healthcare in the acquisition of Repose Furniture.
Limerston Capital has supported its portfolio company Prism Healthcare in the acquisition of Repose Furniture.
Octopus Ventures has announced its intention to launch a £100m healthcare-focused fund.
Healthcare and fintech investor Oak HC/FT has picked up backing from a US pension giant as it looks to raise up to $1.1bn for its latest fund.
Baird Capital has sold Prescient Healthcare Group to Bridgepoint Development Capital (BDC).
UK-based Prescient Healthcare Group is a global provider of pharmaceutical intelligence, insights and product strategy
Healthcare and tech-focused private equity major Welsh, Carson, Anderson & Stowe has brought on board highly experienced health leadership exec Tracy Bahl as an operating partner.
Healthcare and life sciences investor NovaQuest Private Equity has bought contract development and manufacturing organization CoreRx.
Healthcare-focused private equity firm Sheridan Capital Partners has hit a $300m hard cap final close for its first fundraise targeting capital from LPs other than its sole previous investor.
Laxman Pai, Opalesque Asia: Chicago-based healthcare private equity firm Sheridan Capital Partners has collected $306 million for its second fund, with total capital commitments significantly above the $250 million targe...Article Link
Healthcare focused venture firm Heal Capital has hit a €100m final close for its debut fundraise.
Partners in Equity has led a €25m funding round for digital health startup Quin.
Healthtech-focused venture capital firm Heal Capital has held a final close for its debut fund on €100m.
Posted by Mike Turner and Shing Lo, Latham & Watkins LLP, on Friday, January 15, 2021 Editor's Note: Mike Turner and Shing Lo are partners at Latham & Watkins LLP. This post is based on
Redalpine has led a series-A funding round for Germany-headquartered pet healthcare startup Felmo.
Forbion, Morningside Ventures and Ascendant BioCapital have led a $196m series-A funding round for Dutch clinical-stage biotechnology company NewAmsterdam Pharma (NAP).
